Evinature’s CurQD® Protocol took center stage earlier this month at the Crohn’s & Colitis Congress® (CCC) in San Francisco, where leading gastroenterologists and researchers from around the world gathered to discuss the latest advancements in IBD treatment. CurQD® was featured prominently in several key presentations, underscoring its growing role in integrative IBD care.
Groundbreaking Research from Mayo Clinic
One of the most significant moments at the CCC came from Dr. Jami Kinnucan of the Mayo Clinic, who presented compelling new research on the efficacy of CurQD® as part of IBD treatment plans. Her lecture, attended by a wide audience of healthcare professionals, showcased data highlighting how CurQD® can enhance the effectiveness of standard IBD therapies, offering new hope for patients managing Crohn’s disease and ulcerative colitis.
New Findings on CurQD® and Vedolizumab Combination
Adding to the body of evidence supporting CurQD®, Dr. Prof. Milan Lukas, a leading IBD expert from Prague, presented his recent study on the combination of CurQD® with Vedolizumab for active IBD.
His findings suggest that the protocol may serve as a potent adjunct therapy, improving patient outcomes when used alongside biologic treatments.
Clinical Evidence from Mount Sinai Medical Center
Further validating CurQD®’s role in real-world clinical settings, Dr. Jellyana Peraza from Mount Sinai Medical Center shared her latest published study. Dr. Peraza’s research focused on IBD patients who were not responding to biologic treatments and examined how CurQD® could be utilized as an adjunct therapy. Her findings provided promising evidence of CurQD®’s effectiveness in difficult-to-treat cases, highlighting its potential to support patients facing limited options.
Advancing IBD Care
The presentations at this year’s Crohn’s & Colitis Congress® underscore CurQD®’s growing impact in the IBD community. As more clinical evidence emerges, CurQD® continues to gain recognition as a valuable tool in the evolving landscape of IBD treatment.
Stay tuned for more updates as Evinature remains committed to supporting ongoing research and advancing care for individuals living with IBD and other gut health conditions.
Summer Pitocchelli-Schwartzman
